Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

Inclusion Criteria: * Age 18 through 30 years at the screening visit * Physician diagnosis of asthma * Onset of asthma during childhood * Evidence of atopy, evidenced by allergic rhinitis, aeroallergen sensitization, elevated total immunoglobulin E (IgE) level based on age-dependent reference values, or blood eosinophil counts \> or = 150 cells/microliter * Moderate-to-severe persistent asthma as defined by the National Asthma Education and Prevention Program Expert Panel Report-4 Exclusion criteria at the screening visit include any of the following (\*may be re-enrolled): * A Panel Reactive Antibodies (PRA) test is positive for human leukocyte antigens (HLA) antibodies against the γMSC product * Oral or injectable corticosteroid use within the two-week period prior to the screening visit.\* Nasal corticosteroids may be used at any time during this trial at the discretion of the study's Medical Principal Investigator. * Use of medications known to significantly interact with corticosteroid disposition within the two-week period prior to the screening visit, including but not limited to carbamazepine, erythromycin or other macrolide antibiotics, phenobarbital, phenytoin, rifampin, and ketoconazole\* * Presence of chronic or active lung disease other than asthma, including disorders of the airways or chest wall * Current smoking or vaping * History of premature birth before 35 weeks gestation * Significant medical illness other than asthma, including thyroid disease, diabet…